Preparing for COVID-19 vaccine safety surveillance: A United States perspective.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Adverse Events Following mRNA COVID-19 Vaccine in 2021 and 2022: A Retrospective Analysis in Costa Rica and Italy.Cureus · 2023
   Article
2. Risk of admission to hospital with arterial or venous thromboembolism among patients diagnosed in the ambulatory setting with covid-19 compared with influenza: retrospective cohort study.BMJ medicine · 2023
   Article
3. Combining Influenza and COVID-19 Booster Vaccination Strategy to Improve Vaccination Uptake Necessary for Managing the Health Pandemic: A Systematic Review and Meta-Analysis.Vaccines · 2022
   Article
4. The Joint Effects of Social Norm Appeals and Fear Appeals in COVID-19 Vaccine Campaign Posters on Self-Perceived Communication Quality and Vaccination Intention.Frontiers in psychology · 2022
   Article
5. Expression of SARS-CoV-2 Spike Protein Receptor Binding Domain on RecombinantVaccines · 2021
   Article
6. Tracking the progress in COVID-19 and vaccine safety research - a comprehensive bibliometric analysis of publications indexed in Scopus database.Human vaccines & immunotherapeutics · 2021
   Article
7. "First Do No Harm". No-Fault Compensation Program for COVID-19 Vaccines as Feasibility and Wisdom of a Policy Instrument to Mitigate Vaccine Hesitancy.Vaccines · 2021
   Review
8. Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China.Human vaccines & immunotherapeutics · 2021
   Article
9. Comment on Ellenberg and Morris: The role of statisticians in vaccine surveillance.Statistics in medicine · 2021
   Article
10. Preparing for COVID-19 vaccine safety surveillance: A United States perspective.Pharmacoepidemiology and drug safety · 2020
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as